SEK690.00
1.40% today
Stockholm, Jul 16, 05:29 pm CET
ISIN
SE0007692850
Symbol
CAMX
Sector
Industry

Camurus Stock price

SEK690.00
+87.00 14.43% 1M
+104.50 17.85% 6M
+124.50 22.02% YTD
+13.50 2.00% 1Y
+464.80 206.39% 3Y
+520.00 305.88% 5Y
+624.00 945.45% 10Y
+624.00 945.45% 20Y
Stockholm, Closing price Wed, Jul 16 2025
+9.50 1.40%
ISIN
SE0007692850
Symbol
CAMX
Sector
Industry

Key metrics

Basic
Market capitalization
SEK41.0b
Enterprise Value
SEK38.2b
Net debt
positive
Cash
SEK2.9b
Shares outstanding
58.9m
Valuation (TTM | estimate)
P/E
74.3 | 41.0
P/S
20.1 | 14.0
EV/Sales
18.8 | 13.1
EV/FCF
103.7
P/B
11.8
Financial Health
Equity Ratio
87.6%
Return on Equity
13.0%
ROCE
17.6%
ROIC
50.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
SEK2.0b | SEK2.9b
EBITDA
SEK646.0m | SEK1.1b
EBIT
SEK629.4m | SEK1.1b
Net Income
SEK547.8m | SEK978.0m
Free Cash Flow
SEK368.2m
Growth (TTM | estimate)
Revenue
11.7% | 56.7%
EBITDA
18.6% | 126.8%
EBIT
18.7% | 125.9%
Net Income
21.6% | 128.3%
Free Cash Flow
-39.5%
Margin (TTM | estimate)
Gross
93.2%
EBITDA
31.7% | 37.7%
EBIT
30.9%
Net
26.9% | 33.4%
Free Cash Flow
18.1%
More
EPS
SEK9.2
FCF per Share
SEK6.3
Short interest
-
Employees
256
Rev per Employee
SEK7.3m
Show more

Is Camurus a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Camurus Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Camurus forecast:

11x Buy
79%
3x Hold
21%

Analyst Opinions

14 Analysts have issued a Camurus forecast:

Buy
79%
Hold
21%

Financial data from Camurus

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,036 2,036
12% 12%
100%
- Direct Costs 138 138
11% 11%
7%
1,898 1,898
12% 12%
93%
- Selling and Administrative Expenses 632 632
41% 41%
31%
- Research and Development Expense 635 635
12% 12%
31%
646 646
19% 19%
32%
- Depreciation and Amortization 17 17
15% 15%
1%
EBIT (Operating Income) EBIT 629 629
19% 19%
31%
Net Profit 548 548
22% 22%
27%

In millions SEK.

Don't miss a Thing! We will send you all news about Camurus directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.

Head office Sweden
CEO Sven Tiberg
Employees 256
Founded 2004
Website www.camurus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today